
AbbVie Inc. (NYSE: ABBV) is trading near an all-time high after the company announced a licensing agreement with Gubra, a Danish company. The agreement pertains to Gubra’s experimental weight loss drug, which is in a Phase 1 trial.
AbbVie paid Gubra a $350 million upfront payment for the right to its experimental weight loss drug, GUB014295, which is in a Phase 1 trial. AbbVie has committed to paying Gubra up to $1.9 billion based on certain development and sales milestones that are met.